Old Web
English
Sign In
Acemap
>
authorDetail
>
Susan H. Hamil
Susan H. Hamil
University of Virginia
Chronic lymphocytic leukemia
Cell
CD20
Immunology
Rituximab
3
Papers
129
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Predictive Monitoring: IMPact in Acute Care Cardiology Trial (PM-IMPACCT) - A Randomized Clinical Trial Protocol.
2021
JMIR Research Protocols
Jessica Keim-Malpass
Sarah J. Ratcliffe
Liza P. Moorman
Matthew T. Clark
Katherine N Krahn
Oliver J Monfredi
Susan H. Hamil
Gholamreza Yousefvand
J. Randall Moorman
Jamieson M. Bourque
Show All
Source
Cite
Save
Citations (0)
Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia
2006
Journal of Immunology
Michael E. Williams
John J. Densmore
Andrew W. Pawluczkowycz
Paul V. Beum
Adam D. Kennedy
Margaret A. Lindorfer
Susan H. Hamil
Jane C. Eggleton
Ronald P. Taylor
Show All
Source
Cite
Save
Citations (129)
Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.
2005
Blood
Michael E. Williams
John J. Densmore
Andrew W. Pawluczkowycz
Paul V. Beum
Adam D. Kennedy
Margaret A. Lindorfer
Susan H. Hamil
Gina R. Petroni
Jane C. Eggleton
Ronald P. Taylor
Show All
Source
Cite
Save
Citations (0)
1